Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch - CNBC
AI Summary1 min read
TL;DR
Eli Lilly's CEO highlights that Medicare coverage for obesity drugs could significantly impact the launch of their upcoming oral pill, potentially transforming weight loss treatment options and increasing accessibility.
- Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch CNBC
- Recent Trends in GLP-1 Use and Spending in Medicare KFF
- Medicare Coverage of Ozempic Could Change Weight Loss Treatment Options—CEO Newsweek
- Eli Lilly's Oral Obesity Drug Set for Medicare Coverage Intellectia AI
- Medicare Will Start Paying for Weight Loss Drugs Soon — but There’s a Catch Money Talks News